Compounds targeting the individual enzymes of kynurenine-nicotinamide pathway have led to new neuropharmacological concepts and provide novel opportunities for therapeutic intervention. Tryptophan pyrrolase (Tryptophan-2, 3-dioxygenase; EC 1.13.11.11), a metalloprotein, is the first and rate limiting enzyme of the most important pathway for tryptophan metabolism via kynurenine-nicotinamide pathway in the liver and therefore plays a key role in regulating the physiological flux of tryptophan in to relevant metabolic pathways like synthesis of neurotransmitter, serotonin in the brain. Fluoxetine, a clinically proven antidepressant, have shown statistically significant, inhibition of hepatic tryptophan pyrrolase activities (holo, total and apo form) in both the sexes of rats at 10 & 30 mg/kg doses. Despite elevated holo-enzyme form of tryptophan pyrrolase in female rats, we have found similar inhibition of tryptophan pyrrolase activity by Fluoxetine hydrochloride in both -male and female rats. The results are discussed in relation to gender differences in the enzyme activity and its possible role in pathophysiology of depression in females.